CompletedPHASE2, PHASE3NCT00527228
Deflazacort in Dysferlinopathies
Studying Dysferlin-related limb-girdle muscular dystrophy R2
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ludwig-Maximilians - University of Munich
- Principal Investigator
- Maggie C. Walter, MDFriedrich-Baur-Institute, Dept. of Neurology, Ludwig-Maximilians-University of Munich, Germany
- Intervention
- deflazacort(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2003 – 2008
Study locations (1)
- Friedrich-Baur-Institute, Dept. of Neurology, Ludwig-Maximilians-University of Munich, Munich, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00527228 on ClinicalTrials.govOther trials for Dysferlin-related limb-girdle muscular dystrophy R2
Additional recruiting or active studies for the same condition.
See all trials for Dysferlin-related limb-girdle muscular dystrophy R2 →